ORGANIGRAM GLOBAL INC.
For the period ended Dec 31, 2025. Filed Dec 31, 2025.
View on SEC.govAbout this filing
What a company based outside the US has published at home or sent to its shareholders. It is how many foreign companies share results and news between annual reports.
Dec 31, 2025 · Filed Dec 31, 2025
Use the contents to explore the available documents and sections.
Contents
EX-99.1 · International Exclusivity for Genetics
International Exclusivity for Genetics
Under the amended product agreement, Organigram receives five-year exclusivity on its chosen autoflower cultivars across international markets, including Canada, Australia, the UK, Germany, and Israel, with the ability to add new exclusive territories as it expands globally. Annual portfolio reviews will maintain exclusivity only for commercially relevant cultivars, maximising flexibility and strengthening Organigram’s international product differentiation strategy as it enters high-value medical markets.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.